We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.
- Authors
Barril, G.; Quiroga, J. A.; Sanz, P.; Rodrìguez‐Salvanés, F.; Selgas, R.; Carreño, V.
- Abstract
: Therapeutics in end-stage renal disease (ESRD) patients undergoing haemodialysis (HD) has to consider potential drug clearance during the dialysis procedure. Pegylated interferon- α (PEG-IFN- α), a middle-size protein drug active against viral hepatitis, allows convenient once-weekly dosing due to prolonged plasma half-life. : To investigate the impact of permeability and dialyser pore size on PEG-IFN- α blood levels during experimental HD. : Polymethylmetacrylate (PMMA) membrane 1.6 m2 dialysers with three different permeabilities/pore sizes were selected. : A 40 kDa PEG-IFN- α2a (PEGASYS) was not cleared (< 5%) through low-flux/small pore size (25 Å;B3A) and high-flux/middle-large pore size (60 Å;BKP) dialysers, and was partially (≈15%) through intermediate permeability/large pore size (100 Å;BKF) dialysers. In contrast, unmodified 17 kDa IFN- α2a(Roferon-A) was removed (65%–95%) through BKP or BKF, but not B3A, PMMA dialysers. Moreover, 12 kDaPEG-IFN- α2b(PegIntron) was cleared (40%–80%) through PMMA dialysers with pore sizes ≥ 60 Å. When B3A or BKP were replaced every hour PEG-IFN- α2a plasma levels remained constant throughout three experimental-HD-sessions, but PEG-IFN- α2b was cleared partially every BKP replacement. Porosity differ among high-flux dialysers. Neither PEG-IFN- α2a nor PEG-IFN- α2b were removed after three HD sessions through (27/31/33 Å) pore size polysulphone dialysers. Although PEG-IFN- α2a was not cleared through middle pore-size (43 Å/AN69ST) polyacrylonitrile dialyser, PEG-IFN- α2b was partially removed. : The pharmacokinetics of Peg-IFN- α may vary in a patient on dialysis.
- Subjects
INTERFERONS; DRUG metabolism; HEMODIALYSIS patients; VIRAL hepatitis; KIDNEY diseases; ANTIVIRAL agents; PHARMACOKINETICS
- Publication
Alimentary Pharmacology & Therapeutics, 2004, Vol 20, Issue 1, p37
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2004.02014.x